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Abstract
OBJECTIVES: Donation after circulatory declaration of death (DCDD) could signiﬁcantly improve the number of cardiac grafts for trans-
plantation. Graft evaluation is particularly important in the setting of DCDD given that conditions of cardio-circulatory arrest and warm
ischaemia differ, leading to variable tissue injury. The aim of this study was to identify, at the time of heart procurement, means to
predict contractile recovery following cardioplegic storage and reperfusion using an isolated rat heart model. Identiﬁcation of reliable
approaches to evaluate cardiac grafts is key in the development of protocols for heart transplantation with DCDD.
METHODS: Hearts isolated from anaesthetized male Wistar rats (n = 34) were exposed to various perfusion protocols. To simulate
DCDD conditions, rats were exsanguinated and maintained at 37°C for 15–25 min (warm ischaemia). Isolated hearts were perfused with
modiﬁed Krebs–Henseleit buffer for 10 min (unloaded), arrested with cardioplegia, stored for 3 h at 4°C and then reperfused for 120
min (unloaded for 60 min, then loaded for 60 min). Left ventricular (LV) function was assessed using an intraventricular micro-tip
pressure catheter. Statistical signiﬁcance was determined using the non-parametric Spearman rho correlation analysis.
RESULTS: After 120 min of reperfusion, recovery of LV work measured as developed pressure (DP)-heart rate (HR) product ranged from
0 to 15 ± 6.1 mmHg beats min−1 10−3 following warm ischaemia of 15–25 min. Several haemodynamic parameters measured during
early, unloaded perfusion at the time of heart procurement, including HR and the peak systolic pressure-HR product, correlated signiﬁ-
cantly with contractile recovery after cardioplegic storage and 120 min of reperfusion (P < 0.001). Coronary ﬂow, oxygen consumption
and lactate dehydrogenase release also correlated signiﬁcantly with contractile recovery following cardioplegic storage and 120 min of
reperfusion (P < 0.05).
CONCLUSIONS: Haemodynamic and biochemical parameters measured at the time of organ procurement could serve as predictive
indicators of contractile recovery. We believe that evaluation of graft suitability is feasible prior to transplantation with DCDD, and may,
consequently, increase donor heart availability.
Keywords: Heart transplantation • Non-heart beating donors • Cardiac graft evaluation • Ischaemia-reperfusion • Isolated rat heart •
Donation after cardiac death • Donation after circulatory declaration of death
INTRODUCTION
A major obstacle in heart transplantation is the lack of suitable
donor organs. Indeed, it has been reported that 15% of
patients die while awaiting a donor heart [1]. Furthermore, the
gap between donors and patients is growing and is expected to
worsen in coming years [2]. One potential solution to increase
donor heart availability is organ donation after circulatory
declaration of death (DCDD) [1, 3]. DCDD has been the subject
of renewed interest in recent years, as a potential additional
source of donor organs. Importantly, the use of hearts from
DCDD is expected to increase the donor pool by 17% [1] and
has recently been reported as clinically feasible in certain
situations [4, 5].
Despite the considerable potential of DCDD, this donor popu-
lation has not been adopted for heart procurement so far, mainly
because of concerns regarding damage sustained following warm
ischaemia. In the setting of DCDD, cardiac ischaemia may be
initiated at the time of a precipitating event, such as trauma or
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withdrawal of life support, or at the time of cardiac arrest.
Subsequently, an obligatory ‘stand-off’ period of 10 min after
cardiac arrest must be observed for ethical reasons, during which
time no invasive intervention is permitted [6]. Initially, tissue
damage is reversible, but becomes irreversible with increasing is-
chaemic severity or length [7]. Importantly, pre-clinical reports
provide evidence that hearts are tolerant to warm ischaemia, if
limited to a period of 20–30 min, when sufﬁcient integrity for
transplantation is maintained [8, 9]. Paradoxically, cardiac reperfu-
sion itself causes further injury, mediated by generation of react-
ive oxygen species (ROS), calcium overload, rapid normalization
of pH and inﬂammatory processes. As such, clinical methods to
prolong ischaemic tolerance or reduce ischaemia-reperfusion
damage are critical to promote the use of this donor pool.
In order to take advantage of the potential of cardiac grafts
from DCDD, means to evaluate the suitability of hearts for trans-
plantation are key in the development of clinical protocols. In
the setting of DCDD, variability in tissue injury arising from dif-
fering severities of warm ischaemic damage and subsequent
reperfusion injury are critical aspects that must be considered.
Further complexity arises from the differing categories of DCDD,
which have been deﬁned as follows: dead on arrival at hospital
(Maastricht category I; uncontrolled), unsuccessful resuscitation
(Maastricht category II; uncontrolled), planned withdrawal of
treatment (Maastricht category III; controlled) and brain-dead
patients undergoing a cardiac arrest (Maastricht category IV;
controlled) [10]. Importantly, these categories are likely to vary
with respect to cardiac injury. Although the heart may temporar-
ily continue to pump in an increasingly hypoxic environment
prior to arrest in several of these donor categories, both the left
and right ventricles are typically exposed to pressure and
volume overload only in the setting of asphyxiation, such as
might occur with planned withdrawal of treatment (Maastricht
category III; controlled) [11]. The potential for recovery may thus
differ in situations where death followed asphyxiation vs exsan-
guination, as suggested by a recent study performed in a
porcine DCDD model [12]. To date, few reports have proposed
evaluation methods to predict recovery of cardiac contractile
function in the setting of DCDD. Potential approaches include
the measurement of coronary ﬂow (CF) [13], the use of an iso-
lated myocardial perfusion system [14, 15] or fractional anisot-
ropy [16]; however, the latter two necessitate somewhat lengthy
procedures and specialized equipment. Importantly, we have
recently reported that early reperfusion haemodynamic para-
meters correlate with cardiac recovery in the isolated rat heart
when subjected to ischaemia followed by immediate reperfusion
and recovery [17]. However, conditions used in this study were
somewhat removed from the clinical situation; hearts were
isolated prior to ischaemia, ischaemic temperature was 32°C,
and contractile recovery was evaluated during reperfusion im-
mediately following ischaemia; no period of cardioplegic storage
was included.
In the current study, we aimed to identify means to evaluate
cardiac graft suitability for transplantation using a newly devel-
oped isolated, working rat heart DCDD model. To do so, we
assessed whether haemodynamic and biochemical parameters
measured after a period of in situ warm ischaemia, at the time of
heart procurement, are effective in predicting contractile recov-
ery following subsequent periods of cardioplegic storage and
reperfusion. We believe that evaluation of graft suitability is feas-
ible prior to transplantation with DCDD, and may consequently
increase donor heart availability.
METHODS
Materials
Albumin from bovine serum, palmitic acid, sodium-L-lactate,
L-histidine, L-histidine monohydrochloride monohydrate,
L-tryptophan and α-ketoglutaric acid potassium salt were
obtained from Sigma-Aldrich (Buchs, Switzerland). Insulin was
purchased from Nordisk Pharma (Actrapid® HM 100 IU/ml,
Küsnacht, Switzerland) and dialysis membrane was obtained from
Spectrum Labs (Spectra/por®, Rancho Dominguez, CA, USA). All
other chemicals were purchased from Merck (Darmstadt,
Germany).
Ethics statement
All animal experimental procedures were approved by the
Swiss animal welfare authorities and state veterinary ofﬁce
(Authorization number: 11/11), and were executed in compliance
with the European Convention for Animal Care. Surgery was per-
formed under anaesthesia and all efforts were made to minimize
suffering.
Isolated heart preparation
A modiﬁed isolated working rat heart system was used, as previous-
ly described [18]. Brieﬂy, adult male Wistar rats, fed with standard
laboratory diet ad libitum, were anaesthetized using 100 mg/kg
of ketamine (Narketan®, Vetoquinol AG, Bern, Switzerland) and
10 mg/kg of xylazine (Xylapan®, Vetoquinol AG, Bern, Switzerland)
via an intraperitoneal injection. All hearts were excised and rapidly
placed in ice-cold, modiﬁed Krebs–Henseleit bicarbonate buffer
containing: 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4·7H2O,
1.25 mM CaCl2, 25 mM NaHCO3 and 5.5 mM glucose (buffer A).
Each heart was weighed, the aorta cannulated and retrograde
perfusion started. Excess tissue was then removed for left atrial
cannulation and introduction of the micro-tip pressure catheter
(Millar instruments, Houston, TX, USA) into the left ventricle (LV).
During all aerobic perfusions, buffers were equilibrated with 95%
O2/5% CO2 and maintained at 37°C.
Experimental protocol
Animals were divided into six groups according to perfusion
protocol (Fig. 1A–C).
Experimental groups. For the DCDD model, anaesthetized
rats were heparinized via tail vein injection (60 units; Liquemin®
5000 IE/ml, Drossa Pharma AG, Basel, Switzerland) and then
exsanguinated via the abdominal aorta and maintained at 37°C
for various periods. In this manner, experimental groups with
warm, in situ, global ischaemia for 15, 20 and 25 min were
generated (Fig. 1A).
Immediately following ischaemia, hearts were isolated and
aerobically perfused in a retrograde/Langendorff preparation
with buffer A at a pressure of 60 mmHg for 10 min (procure-
ment perfusion). During this time, a micro-tip pressure catheter
was introduced in the LV and haemodynamic parameters, as
well as CF, were recorded at 10 min.
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Hearts were then arrested with cardioplegia (Custodiol) at 4°C
for 7 min, delivered via Langendorff perfusion at a pressure of
65 mmHg. Cardioplegia contained: 150 mM NaCl, 90 mM KCl,
40 mM MgCl·6H2O, 180 mM L-histidine monohydrochloride
monohydrate, 1800 mM L-histidine, 20 mM L-tryptophan, 300
mM mannitol, 0.15 mM CaCl2·2H2O and 10 mM α-ketoglutaric
acid potassium salt. Immediately following perfusion, hearts
were immersed in cardioplegic solution at 4°C for 180 min.
Following cardioplegic storage, all hearts were aerobically
reperfused for 120 min (implantation reperfusion). Hearts were
initially perfused in an unloaded mode, with a constant aortic
pressure of 60 mmHg for 60 min and then in loaded (working)
mode, with a preload pressure of 11.5 mmHg and an afterload
column of 80 mmHg for 60 min. The implantation reperfusion
buffer contained: 118 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4,
1.2 mM MgSO4·7H2O, 1.25 mM CaCl2, 25 mM NaHCO3, 5.5 mM
glucose, 100 μIU/ml insulin, 3% albumin, 0.5 mM lactate and
1.2 mM palmitic acid (buffer B). High levels of fatty acids were
chosen, as they are known to be elevated in humans undergoing
cardiac surgery [19] and are detrimental to the recovery of con-
tractile function after ischaemia [20]. Concentrations of glucose,
insulin and lactate represent human physiological levels.
Control groups. Three separate control groups were used
(Fig. 1B and C).
One control group was prepared identically to the DCDD
experimental groups (described above), but was not subjected to
warm ischaemia; immediately following exsanguination, the
heart was isolated and perfused with buffer A. A second control
group was generated by directly perfusing hearts with cold
cardioplegic solution; these hearts were subjected neither to
warm ischaemia nor any perfusion prior to cardioplegia. A third
control, the baseline group, comprised hearts without any
pre-treatment (no heparinization, nor exsanguniation) that were
isolated and prepared as described above, and perfused in the
aerobic, loaded mode for 20 min with buffer B.
Data collection
Possible predictive parameters including all haemodynamic and
biochemical parameters were assessed at 10 min of procurement
perfusion and implantation reperfusion. In addition, CF mea-
sured after 5 min of cardioplegic perfusion was considered a
possible predictive parameter. Outcome parameters included
all haemodynamic parameters described below, measured at
120 min of implantation reperfusion.
Haemodynamic parameters. A micro-tip pressure catheter
coupled to a high-performance data acquisition system (PowerLab,
ADInstruments, Spechbach, Germany) was continuously used to
record LV pressure. CF and aortic ﬂow (AF) were measured by
timed collection of coronary efﬂuent and used for the
quantiﬁcation of markers of necrosis and metabolism. These
measurements were taken at 10 min of procurement perfusion and
at 10 and 120 min of implantation reperfusion.
The following haemodynamic parameters were assessed:
(i) heart rate [HR (beats min−1)]
(ii) peak systolic pressure [PSP (mmHg)]
(iii) LV minimum pressure [Pmin (mmHg)]
(iv) LV end-diastolic pressure [EDP (mmHg)]
(v) LV developed pressure [DP (PSP−Pmin; mmHg)]
(vi) maximum and minimum ﬁrst derivatives of LV pressure
[dP/dtmax and dP/dtmin (mmHg s
−1)]
(vii) coronary ﬂow [CF (ml min−1)]
Figure 1: Perfusion protocols. Hearts (n = 34) were divided into six different perfusion groups. DCDD experimental groups are represented in (A) and include
hearts that underwent in situ warm ischaemia followed by 10 min of procurement perfusion, cardioplegic perfusion and storage and implantation reperfusion for
120 min. Three different ischaemic periods were investigated: 15, 20, and 25 min. Control groups (B and C) comprised either 10 min of procurement perfusion,
followed by cardioplegia and 120 min of reperfusion, direct cardioplegic perfusion and storage followed by 120 min of reperfusion, or 20 min of loaded aerobic
perfusion.
B
A
SI
C
SC
IE
N
C
E
J. Sourdon et al. / European Journal of Cardio-Thoracic Surgery e89
(viii) cardiac output [CO (CF + AF; ml min−1)]
(ix) LV work
(1) PSP-HR product (mmHg beats min−1),
(2) DP-HR product (mmHg beats min−1),
(3) DP-HR-CO product (mmHg beats ml min−2),
(4) Triple product-PSP [TP (PSP) (PSP × dP/dtmax × HR; mmHg
2
beats min−1 s−1)] and
(5) Triple product-DP [TP (DP) (DP × dP/dtmax × HR; mmHg
2
beats min−1 s−1)].
Markers of necrosis and metabolism. Lactate dehydrogenase
release (LDH, mU min−1 g wet−1) was measured with a Roche
MODULAR P800 analyser (Roche Diagnostics Corp., Indianapolis, IN,
USA), and troponin T release (TnT, ng min−1 g wet−1) was measured
with a Roche MODULAR E170 analyser (Roche, Basel, Switzerland)
and an electro-chemiluminescense-immunoassay analyser (Roche,
Basel, Switzerland). Markers of metabolism included oxygen
consumption (O2C, mmHg ml
−1 min−1 g wet−1), assessed using an
iSTAT analyser (Abbott, Baar, Switzerland), and lactate release (μmol
min−1 g wet−1), measured with a Roche/Hitachi MODULAR P
analyser (Roche Diagnostics Corp., Mannheim, Germany).
Data analysis
Percentage recovery of each parameter for all hearts was assessed
using baseline haemodynamic parameters. Unless stated otherwise,
values are reported as mean ± SD. SPSS for Windows (version 17.0,
SPSS, Inc., Chicago, IL, USA) was used for data analysis. A Kruskal–
Wallis test was employed for an overview of differences between
experimental groups. When signiﬁcant overall results were
observed, Mann–Whitney analysis was performed for comparisons
between groups of particular interest at speciﬁc time points.
Among hearts exposed to 15–25 min of ischaemia,
Spearman’s rho analysis was used to investigate correlations
between potential predictive parameters measured at 10 min of
procurement perfusion or 5 min of cardioplegic perfusion and
outcome parameters. In addition, correlations between potential
predictive parameters measured at 10 min of implantation
reperfusion and outcome parameters were analysed. The most
effective approach for predicting the suitability/non-suitability of
a heart for transplantation after a period of in situ warm ischae-
mia was investigated by comparing predictive abilities of para-
meters measured at 10 min of procurement perfusion with
outcome parameters. First, hearts were designated as those that
recovered if percentage recovery of DP × HR product ≥40% base-
line value or as those that did not recover if recovery of DP × HR
product <40%. Hearts were then categorized as ‘predicted to
recover’ or as ‘predicted not to recover’ according to threshold
cut-off limits and veriﬁed against the actual measured recovery
of DP × HR product after 120 min of implantation reperfusion.
Correct positives (recovery) and negatives (no recovery), as well
as false positives and negatives, were determined.
The sequential rejective Bonferroni procedure was used to
correct for multiple comparisons and tests [21]. With this
approach, families of parameters, rather than individual para-
meters, are considered for correcting P-values in order to
prevent an overly severe correction [21]. To do so, three families
of parameters were considered: baseline physiological para-
meters, haemodynamic parameters and biochemical parameters.
All P-values were reported after correction. Corrected
P-values < 0.05 were considered statistically signiﬁcant.
RESULTS
An overview of the Kruskal–Wallis tests is provided in the
Supplementary Table.
Baseline characteristics
A total of 34 hearts were analysed in this study. Heart and body
weights for each group are presented in Table 1. No difference
was observed among groups for body weight. Heart weight for
the 0-min ischaemic group was signiﬁcantly lower than in the
baseline group; that for 15- and 20-min ischaemic groups was
higher than in the 0-min ischaemic group; and that for the
25-min ischaemic group was lower than in baseline and 15-min
ischaemic groups (P < 0.05 for all comparisons).
Haemodynamic function
Haemodynamic function measured as DP × HR and CO at the
end of the experimental protocol decreased with increasing
length of warm ischaemia (Fig. 2A and B). Outcome parameters
expressed as absolute value and as percent recovery are
presented in Table 2.
Table 1: Baseline characteristics
Groups
All hearts Baseline Directly cardiopleged Ischaemic time
0 min 15 min 20 min 25 min
Number of hearts (n) 34 5 6 6 6 6 5
Body weight (g) 349.2 ± 52 382.6 ± 13.4 387.2 ± 33.5 305.2 ± 67.3 347.7 ± 26.2 339.0 ± 53.5 337.2 ± 62.5
Heart weight (g) 1.5 ± 0.2 1.7 ± 0.1 1.5 ± 0.3 1.3 ± 0.1a 1.7 ± 0.2b 1.6 ± 0.1b 1.3 ± 0.2a,c
Data are expressed as mean ± SD.
aP < 0.05 vs baseline.
bP < 0.05 vs 0 min of ischaemia.
cP < 0.05 vs 15 min of ischaemia.
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Predictive parameters
Predictive parameters measured at 10 min of procurement
perfusion or at 5 min of cardioplegic perfusion are presented in
Table 3, whereas predictive parameters measured at 10 min of
implantation reperfusion are presented in Table 4.
Relationships between predictive and outcome
parameters
Several parameters assessed at 10 min of procurement perfusion
correlated signiﬁcantly with outcome parameters measured
during the subsequent loaded implantation reperfusion phase.
An overview of these correlations is shown in Figure 3A. Of the
parameters assessed at 10 min of procurement perfusion,
DP × HR, PSP × HR and LDH release were among those that
resulted in the greatest number of strong correlations (P < 0.001)
and were the only three parameters that correlated strongly
(P < 0.001) with all outcome measures of LV work. CF (at 10 min
of procurement perfusion and at 5 min of cardioplegic perfu-
sion) and oxygen consumption correlated with almost all
outcome parameters.
An overview of the correlation between predictive parameters
measured at 10 min of unloaded implantation reperfusion and
outcome parameters is provided in Figure 3B. Similar to predict-
ive parameters measured during the procurement perfusion,
several haemodynamic parameters measured during the im-
plantation reperfusion correlated with outcome parameters. CF
and LDH release gave the greatest number of strong correlations
(P < 0.001) with all outcome parameters, while CF gave the stron-
gest correlation (P < 0.001) with outcome measures of LV work.
A comparison of the relationships between predictive para-
meters measured either at procurement or at implantation and
outcome parameters revealed that most potential predictive
parameters were associated with outcomes when measured at
either time point (Fig. 3C). However, predictive parameters that
gave the greatest number of strong correlations with outcome
measures of LV work when measured during procurement perfu-
sion were less strongly associated with outcome parameters
when measured during implantation reperfusion. Interestingly,
TnT release and CF demonstrate a greater number of
correlations with outcome parameters when evaluated at 10 min
of implantation reperfusion vs 10 min of procurement perfusion
(Fig. 3C).
Evaluation of predictive parameters
The ability of predictive parameters to correctly predict subse-
quent outcomes was evaluated (Table 5). HR, PSP × HR product
and LDH release assessed during the initial 10 min of procure-
ment perfusion appeared most effective for graft evaluation;
compared with other predictive parameters, HR, PSP × HR
product and LDH release could be used to best predict whether
hearts would subsequently recover or not, without generating
any false positives.
DISCUSSION
Increasing the pool of cardiac grafts is a major challenge in
organ procurement for transplantation. We demonstrate that
contractile and biochemical parameters assessed during an
unloaded procurement perfusion correlate well with contractile
recovery following cardioplegia and reperfusion. This study was
performed in a new DCDD rat model, which includes a period
of warm, global, in situ ischaemia and 3 h of cardioplegic
storage. Our ﬁndings provide evidence that the assessment of
haemodynamic and biochemical parameters in DCDD heart
grafts at the time of procurement may facilitate evaluation of
suitability for subsequent transplantation. This approach could
be useful for cardiac graft assessment in general, and particularly
in the context of transplantation with DCDD.
In order to simulate DCDD conditions, hearts were subjected
to in situ warm ischaemia following exsanguination and cardio-
plegic storage. In a previous study, we proposed that haemo-
dynamic parameters assessed during early, unloaded reperfusion
may be useful to predict subsequent contractile heart recovery
[17]. However, conditions used at this time were somewhat
removed from the clinical situation; hearts were isolated prior to
ischaemia, ischaemic temperature was 32°C and no period of
cardioplegic storage was included. In the present study, we
extend our ﬁndings by demonstrating that early reperfusion
Figure 2: Haemodynamic recovery. Haemodynamic recovery measured at the end of the perfusion protocol for hearts subjected or not to in situ warm ischaemia
(Groups 1–6) as HR—DP product (A) or as CO (B).
B
A
SI
C
SC
IE
N
C
E
J. Sourdon et al. / European Journal of Cardio-Thoracic Surgery e91
Table 2: Haemodynamic parameters and CF at 120 min of reperfusion
Groups
Baseline Directly cardiopleged Ischaemic time
0 min 15 min 20 min 25 min
Abs 1200 % Abs 1200 % Abs 1200 % Abs 1200 % Abs 1200 %
HR (beats min−1) 225 ± 38 230 ± 59 102 ± 26 196 ± 57 87 ± 25 169 ± 66 75 ± 29 153 ± 41 68 ± 18 0 ± 0a,b,c,d,e 0 ± 0b,c,d,e
PSP (mmHg) 128 ± 15 116 ± 10 89 ± 8.0 120 ± 17 92 ± 13 97 ± 12a,c 75 ± 9.0c 77 ± 15a,b,c 59 ± 12b,c 0 ± 0a,b,c,d,e 0 ± 0b,c,d,e
DP (mmHg) 130 ± 15 108 ± 9.9 83 ± 7.7 110 ± 15 85 ± 11 89 ± 13 68 ± 9.8 65 ± 23a,b,c 50 ± 17b,c 0 ± 0a,b,c,d,e 0 ± 0b,c,d,e
dP/dtmin (mmHg s
−1 10−2) −30 ± 3.2 −26 ± 5.9 89 ± 20 −26 ± 4.5 88 ± 15 −19 ± 3.2a,b,c 64 ± 11b,c −13 ± 4.1a,b,c 44 ± 14b,c 0 ± 0a,c 0 ± 0b,c,d,e
dP/dtmax (mmHg s
−1 10−2) 47 ± 15 32 ± 3.8 69 ± 8.0 29 ± 14 62 ± 30 26 ± 3.8a,b 54 ± 8.1b 19 ± 5.8a,b,d 41 ± 12b 0 ± 0a,b,c,d,e 0 ± 0b,c,d,e
PSP × HR (mmHg beats min−1 10−3) 29 ± 2.1 26 ± 5.7 91 ± 20 23 ± 5.7 80 ± 20 16 ± 6.3a,b 57 ± 22b 12 ± 3.6a,b,c 41 ± 13b,c 0 ± 0a,b,c,d,e 0 ± 0b,c,d,e
DP × HR (mmHg beats min−1 10−3) 29 ± 2.1 24 ± 5.2 85 ± 18 21 ± 5.1a 74 ± 18 15 ± 6.1a,b 52 ± 21b 9.9 ± 4.1a,b,c 34 ± 14b,c 0 ± 0a,b,c,d,e 0 ± 0b,c,d,e
DP × HR × CO (mmHg beats ml min−2 10−4) 127 ± 49 94 ± 36 74 ± 28 37 ± 19a,b 29 ± 15b 28 ± 20a,b 22 ± 17b 10 ± 6.4a,b,c 8.0 ± 5.0b,c 0 ± 0a,b,c,d,e 0 ± 0b,c,d,e
TP (PSP) (mmHg2 beats min−1 s−1 10−6) 135 ± 36 85 ± 22 63 ± 16 66 ± 36a 49 ± 27 43 ± 19a,b 32 ± 14b 23 ± 11a,b 17 ± 8.0b 0 ± 0a,b,c,d,e 0 ± 0b,c,d,e
TP (DP) (mmHg2 beats min−1 s−1 10−6) 135 ± 36 79 ± 20a 59 ± 15 61 ± 33a 45 ± 25 40 ± 18a,b 29 ± 13b 20 ± 11a,b 15 ± 8.1b 0 ± 0a,b,c,d,e 0 ± 0b,c,d,e
CF (ml min−1) 17 ± 4.0 19 ± 9 109 ± 53 16 ± 2.4 90 ± 14 15 ± 5.0 86 ± 29 9.1 ± 4.2b,c 52 ± 24b,c 0 ± 0a,b,c,d,e 0 ± 0b,c,d,e
CO (ml min−1) 44 ± 13 27 ± 13 61 ± 29 23 ± 6.7 52 ± 15 17 ± 8.3 39 ± 19 9.1 ± 4.2a,b,c 21 ± 9.5b,c 0 ± 0a,b,c,d,e 0 ± 0b,c,d,e
Data are expressed as mean ± SD.
aP < 0.05 vs baseline.
bP < 0.05 vs directly cardiopleged.
cP < 0.05 vs 0 min of ischaemia.
dP < 0.05 vs 15 min of ischaemia.
eP < 0.05 vs 20 min of ischaemia.
CF: coronary flow; CO: cardiac output; dP/dtmin and max: minimum and maximum first derivatives of LV pressure; DP: developed pressure; HR: heart rate; PSP: LV peak systolic pressure; TP (DP): triple product
(DP)—DP × HR × dP/dtmax; TP (PSP): triple product (PSP)—PSP × HR × dP/dtmax
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Table 4: Predictive parameters at 10 min of reperfusion (implantation reperfusion)
Groups
Directly cardiopleged Ischaemic time
0 min 15 min 20 min 25 min
HR (beats min−1) 194 ± 30 213 ± 28 167 ± 51 175 ± 32 41 ± 56a,b,c,d
Pmin (mmHg) 1.2 ± 4.3 0.3 ± 6.9 1.3 ± 8.0 6.6 ± 8.9 NM
PSP (mmHg) 63 ± 6.1 64 ± 10 74 ± 9.1 59 ± 24 24 ± 34
DP (mmHg) 61 ± 3.7 62 ± 8.3 72 ± 9.4a 52 ± 29 13.5 ± 22a,b,c
dP/dtmin (mmHg s
−1) −1060 ± 101 −1120 ± 214 −1268 ± 323 −923 ± 489 −258 ± 353a,b,c
dP/dtmax (mmHg s
−1) 1425 ± 173 1238 ± 535 1701 ± 413 1292 ± 708 302 ± 414a,b,c
PSP × HR (mmHg beats min−1 10−3) 12 ± 2.6 13 ± 2.1 12 ± 4.1 11 ± 5.0 2.5 ± 3.4a,b,c
DP × HR (mmHg beats min−1 10−3) 12 ± 2.0 13 ± 2.3 12 ± 4.0 9.6 ± 5.7 1.3 ± 2.1a,b,c
DP × HR × CF (mmHg beats ml min−2 10−4) 9.2 ± 2.3 16 ± 3.6 12 ± 5.4 11 ± 6.7 0.3 ± 0.6a
TP (PSP) (mmHg2 beats min−1 s−1 10−6) 18 ± 5.4 17 ± 8.9 21 ± 11 17 ± 12 1.8 ± 2.6
TP (DP) (mmHg2 beats min−1 s−1 10−6) 17 ± 4.4 17 ± 9.1 21 ± 11 16 ± 12 1.0 ± 1.6
EDP (mmHg) 2.5 ± 4.4 1.5 ± 6.8 3.3 ± 7.6 8.1 ± 9.2 NM
CF (ml min−1) 15 ± 2.1 13 ± 3.6 11 ± 1.3a 9.9 ± 2.5a 5.5 ± 2.2a,b
Lactate (μmol min−1 g wet−1) 0.20 ± 0.34 0.50 ± 0.88 0.27 ± 0.18 0.27 ± 0.56 0.17 ± 0.40
TnT (ng min−1 g wet−1) 3.68 ± 2.61 3.18 ± 2.47 4.33 ± 1.72 7.56 ± 6.78 52.34 ± 69.24
LDH (mU min−1 g wet−1) 223 ± 98 247 ± 249 582 ± 187a 729 ± 501 3491 ± 3265a,b,d
O2C (mmHg ml
−1 min−1 g wet−1) 2587 ± 447 2283 ± 785 1604 ± 262a 1566 ± 567a 999 ± 421a,b
Data are expressed as mean ± SD.
aP < 0.05 vs directly cardiopleged.
bP < 0.05 vs 0 min of ischaemia.
cP < 0.05 vs 15 min of ischaemia.
dP < 0.05 vs 20 min of ischaemia.
CF: coronary flow; dP/dtmin and max: minimum and maximum first derivatives of LV pressure; DP: developed pressure; EDP: LV end-diastolic pressure; HR:
heart rate; LDH: lactate dehydrogenase; O2C: oxygen consumption; Pmin: LV minimum pressure; TnT: troponin-T; PSP: LV peak systolic pressure; TP (DP):
triple product (DP)—DP × HR × dP/dtmax; TP (PSP): triple product (PSP)—PSP × HR × dP/dtmax: NM = not measurable.
Table 3: Predictive parameters at 10 min of reperfusion (procurement perfusion) and at 5 min of cardioplegia
Groups—ischemic time
0 min 15 min 20 min 25 min
HR (beats min−1) 236 ± 34 175 ± 79 142 ± 77 34 ± 62a
Pmin (mmHg) −2.6 ± 4.5 2.8 ± 7.1 1.6 ± 9.3 NM
PSP (mmHg) 55 ± 17 61 ± 35 49 ± 19 19 ± 32
DP (mmHg) 56 ± 17 58 ± 32 48 ± 22 4.7 ± 6.8a,b,c
dP/dtmin (mmHg s
−1) −1012 ± 320 −979 ± 405 −859 ± 325 −92 ± 127a,b,c
dP/dtmax (mmHg s
−1) 1466 ± 423 1320 ± 524 1351 ± 671 111 ± 152a,b,c
PSP × HR (mmHg beats min−1 10−3) 13 ± 4.1 8.8 ± 2.3 6.8 ± 4.3 1.1 ± 1.6a,b,c
DP × HR (mmHg beats min−1 10−3) 13 ± 3.9 8.6 ± 2.1 6.9 ± 4.4 0.5 ± 0.9a,b,c
DP × HR × CF (mmHg beats ml min−2 10−4) 11 ± 3.1 8.0 ± 2.7 8.0 ± 6.4 1.5 ± 2.8a,b,c
TP (PSP) (mmHg2 beats min−1 s−1 10−6) 20 ± 12 12 ± 7.1 11 ± 9.3 3.1 ± 4.4a,b,c
TP (DP) (mmHg2 beats min−1 s−1 10−6) 20 ± 12 12 ± 6.5 11 ± 9.0 1.3 ± 2.5a,b,c
EDP (mmHg) −1.5 ± 4.3 4.7 ± 7.5 3.3 ± 9.9 NM
CF (ml min−1) 8.3 ± 1.5 10 ± 1.1 10 ± 1.9 3.1 ± 1.3a
Coronary cardioplegic flow (ml min−1) 10 ± 1.8 10 ± 1.7 7.9 ± 0.8b 4.7 ± 1.6a
Lactate (μmol min−1 g wet−1) 0.14 ± 0.1 0.31 ± 0.27 0.45 ± 0.20 0.39 ± 0.08
TnT (ng min−1 g wet−1) 0.15 ± 0.11 0.60 ± 0.34 0.93 ± 0.60 0.73 ± 0.45
LDH (mU min−1 g wet−1) 0.0 ± 0.0 46 ± 53 66 ± 56a 795 ± 69a,c
O2C (mmHg ml
−1 min−1 g wet−1) 1783 ± 581 1713 ± 130 1901 ± 487 634 ± 229
Data are expressed as mean ± SD. NM = not measurable.
aP < 0.05 vs 0 min of ischaemia
bP < 0.05 vs 15 min of ischaemia.
cP < 0.05 vs 20 min of ischaemia.
CF: coronary flow; dP/dtmin and max: minimum and maximum first derivatives of LV pressure; DP: developed pressure; EDP: LV end-diastolic pressure; HR:
heart rate; LDH: lactate dehydrogenase; O2C: oxygen consumption; Pmin: LV minimum pressure; TnT: troponin-T; PSP: LV peak systolic pressure; TP (DP):
triple product (DP)—DP × HR × dP/dtmax; TP (PSP): triple product (PSP)—PSP × HR × dP/dtmax.
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predictive parameters are indeed effective in a model that is
closer to the clinical setting of DCDD. Speciﬁcally, hearts were
subjected to an in situ ischaemia at 37°C and a second period of
ischaemia in which cardioplegia was included. In addition, rats
were not given any pre-treatment, with the exception of
heparin, which, according to local regulations, may or may not
be permitted in the clinical setting. Recovery of 52% (measured
as DP × HR relative to baseline) was found after 15 min of warm
in situ ischaemia and 3 h of cold cardioplegia (Table 2). These
ﬁndings are in agreement with previous reports of heart recov-
ery in other DCDD models [8, 9]. Importantly, no difference in
recovery was found between the directly cardiopleged group
and the 0-min ischaemic group, which suggests that, under
these conditions, a brief, unloaded reperfusion prior to cardio-
plegia is well tolerated by the heart. Furthermore, it is note-
worthy that this brief, unloaded reperfusion provides a window
of opportunity, not only to assess heart suitability after a stand-
off period in the setting of DCDD as we describe here, but also
to potentially treat hearts, for example, with anti-oedemic
agents, scavengers of oxygen radicals or calcium-channel block-
ers, so that subsequent recovery is optimized.
Several early reperfusion predictive parameters strongly corre-
lated with outcome parameters. In agreement with our previous
ﬁndings, measures of left ventricular work (DP × HR, PSP × HR or as
TP (DP) and TP (PSP)) correlated well with outcome parameters.
However, in contrast to our previous work, Pmin and EDP during
early reperfusion did not correlate with outcomes. Importantly, the
current study, which represents a more ‘realistic’ model of trans-
plantation, provides evidence that Pmin and EDP are less attractive
candidates than measures of LV work for the prediction of graft
suitability. Furthermore, we demonstrate that, immediately follow-
ing ischaemia, early procurement perfusion measures of oxygen
consumption and release of LDH correlated with most outcome
parameters including all measures of LV work. Interestingly, TnT
release was more closely associated with outcome parameters
when measured during early implantation reperfusion compared
with procurement perfusion. This ﬁnding most probably results
from the delay in the release of TnT following cardiac damage and
suggests that assessment of LDH is preferable to TnT for the evalu-
ation of cardiac grafts at the time of procurement.
In the current study, exsanguination has been used to induce
cardiac death. It is, however, critical to note that this approach
is not necessarily representative of all candidates for DCDD.
Importantly, multiple aspects of transplantation with DCDD
remain under intense discussion and current practices vary from
country to country [22, 23]. In particular, it is unclear whether
heart transplantation with DCDD will become widespread and
whether all categories of donors will be considered acceptable
for heart donation. On the one hand, it would seem logical
that patients undergoing planned withdrawal of treatment
(Maastricht category III) may become the donor of preference,
as the conditions surrounding the cardiac arrest can be closely
monitored. On the other hand, it may be that donors who have
undergone cardiac arrest subsequent to exsanguination, i.e.
exposed to less damaging conditions for the heart when com-
pared with asphyxiation, will be preferred [12]. In the case of our
current study, the primary aim was to determine whether para-
meters measured at the time of procurement could provide an
indication of post-cardioplegic recovery, and thus conditions
surrounding donor death were chosen to generate three groups
of reproducible, but distinct, levels of recovery. Obviously,
further studies are required to investigate the validity of the
identiﬁed predictive parameters in other DCDD models, includ-
ing models in which death is induced by asphyxiation.
Figure 3: Spearman correlations between predictive and outcome parameters. Spearman’s rho analysis was used to investigate relationships between potential
predictive and outcome parameters: overview of correlations between predictive parameters measured prior to cardioplegic storage and outcome parameters (A);
overview of correlations between predictive parameters measured immediately following cardioplegic storage and outcome parameters (B); comparison of rela-
tionships between predictive parameters measured at different time points and outcome parameters (C).
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For eventual translation to clinical practice, predictive para-
meters must provide rapid and reliable information to support
the ‘yes or no’ decision to proceed with transplantation following
organ procurement. Furthermore, predictive parameters must
demonstrate a low rate of false positives (wrongly classiﬁed as
suitable for transplantation) because the use of such an organ as
a cardiac graft would have fatal consequences. Under our experi-
mental conditions, we demonstrate that LDH release, HR and
PSP × HR were the most effective parameters for graft evaluation
as they could be used to most accurately predict which hearts
would subsequently recover (or not) without generating false
positives. Similar to our previous ﬁndings, parameters associated
with cardiac recovery reported by other groups, such as lactate
release [24] and CF [13], appear to be less promising than other
biochemical or haemodynamic measures in our model. Taken
together, LDH release, HR and HR × PSP appear to be the most
promising parameters to be pursued in the development of
eventual clinical protocols.
Summary
We believe that evaluation of graft suitability is feasible prior to
transplantation with DCDD and may consequently increase
donor heart availability. All cardiac grafts used for transplantation
are exposed to damaging situations, not only as a result of warm
ischaemia with DCDD, but also as a result of neurological and
haemodynamic instability associated with brain death in conven-
tional donors [25]. As such, evaluation of cardiac graft suitability
is a critical aspect in transplantation. We report that haemo-
dynamic and biochemical analysis may facilitate evaluation of
cardiac grafts at the time of procurement, during a brief,
unloaded reperfusion prior to cardioplegia. This analysis could
be performed in an ex vivo preparation and does not require
specialized equipment. Furthermore, in clinical practice, this
technique could be adopted in the setting of heart transplant-
ation to screen all donors. Since not only ischaemia, but also
reperfusion, causes cardiac damage, graft evaluation after reper-
fusion, as proposed here, may be advantageous. Importantly,
our approach could rapidly provide information permitting a
‘yes or no’ decision with respect to suitability for transplant.
LIMITATIONS
This work demonstrates potential approaches that may be used
towards the development of a clinical protocol for the evaluation
of cardiac grafts from DCDD. Clearly, further investigations are
required prior to the translation of this approach to the clinic.
For example, pre-clinical experiments will be necessary to valid-
ate potential predictive parameters in a larger heart model. In
addition, given that differing DCDD categories, as well as reper-
fusion strategies, are likely to affect post-transplant contractile re-
covery, predictive parameters must be validated under various
conditions in order to identify the most robust parameters for
cardiac graft evaluation. Finally, heart recovery was assessed at
120 min of reperfusion following cardioplegia in the absence of
blood. As such, the validity of our predictive parameters remains
to be investigated with longer-term recovery, as well as with
blood reperfusion.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
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APPENDIX. CONFERENCE DISCUSSION
Dr J. Dinkhuysen (São Paulo, Brazil): I want to say that I published a paper
last year in Revista Brasileira de Cirurgia Cardiovascular on the application of
the non-working-beating-heart in humans. In 20 patients the ischaemic time
was reduced to 45-60 minutes. Using normothermia, the ﬁrst anastomosis we
construct is the aortic, which immediately reperfuses the coronary system,
and the heart is made to beat with a counter-shock. The last anastomoses are
made with the heart beating and there were no problems with the implant. I
think this clinical application is a new step in transplantation because the is-
chaemia time is considerably reduced.
Dr T. Wahlers (Cologne, Germany): Your paper presents relevant experience
in the ﬁeld of experimental heart transplantation from non-heart-beating
donors. Numerous modiﬁed protocols regarding the suitability of potential
marginal cardiac donors have been published over the past 25 years, as we
have recently published in a manuscript in Transplant International.
The practice of using non-heart-beating donors as the "ultimate" marginal
donor has increasingly become a part of transplant programmes worldwide,
even becoming an option in thoracic organ transplantation. Currently,
non-heart-beating donors are clinically used, especially in pulmonary trans-
plantation, in several countries around the world.
Your manuscript is based on a sophisticated small animal model. It gives
further evidence that even heart transplantation could be performed using
these donors. Identiﬁcation of clinically applicable parameters for evaluation
of graft cardiac function have been presented by your group. Also, this ex-
perimental concept might not be directly transferable to clinical standard
practice. I want to ask you two questions.
Which parameters should be used in approaching non-heart-beating
donors in the clinical ﬁeld based on your experience, and since your group
also has extensive experience in clinical heart transplantation, what should be
the next step in order to approach a large animal model? And do you think
the same parameters will work in the big animal models, and do you also
think that perhaps reperfusion time should be increased?
Dr Dornbierer: Concerning your ﬁrst question about which parameter was
probably best, to really have no false-positive cases, we propose that LDH
heart rate and peak systolic pressure-heart rate product probably were the
best or most effective and the safest. But, of course, this needs to be further
validated in another model, including a large animal model.
As to what needs to be done before we can move to the clinic or a larger
animal model, we are in the process of setting up an isolated working system
for pig hearts, but it is quite tricky. We will use this to validate the predictive
parameters. And, of course, we hope to use the same predictive parameters
but we will probably have to consider many more factors as well.
Dr Wahlers: My personal feeling would be that since small hearts and big
hearts are different, perhaps heart rate might be not as sensitive as it is in
your pig model or even in humans. So, therefore, I have a little doubt about
the transfer of all parameters.
Dr Dornbierer: Yes, deﬁnitely; we will see.
Dr J. Dark (Newcastle Upon Tyne, UK): Can I question your method of indu-
cing death? Exsanguination is very far removed from what clinically happens
during DCD donation. I suspect it may be setting up these animals in a very
different fashion. Cardiac distension probably occurs in the clinical setting
and may give you a completely different set of measurements. Would you
like to comment on that?
Dr Dornbierer: For us exsanguination was quite straightforward to use in
our model and we thought for this study that it was also best to compare the
hearts of the rats that underwent the same process of dying. I would say it
was the easiest approach for us. Of course, the most used categories for
non-heart-beating donors may be category III where there is withdrawal of
life support and expected cardiac death. This was technically more difﬁcult to
induce in our model, which is why we chose exsanguination. Although it is
not the only type of non-heart-beating donor, we thought it was a good
model for this study.
Dr Dark: I appreciate that, but I think if you are going to the cost and
expense and complexity of a large animal model, you should simulate what
happens in clinical reality where there is always an agonal phase. There may
be catecholamine released during that phase, and I think it may be having a
very profound effect on these donor hearts.
Dr Dornbierer: Yes, that is true.
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